Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 5/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.56 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 2/20 | 0.54 |
| ▸ | RAB9A | P51151 | 3/20 | 0.52 |
| ▸ | NPC1 | O15118 | 2/20 | 0.52 |
| ▸ | CNR2 | P34972 | 3/20 | 0.50 |
| ▸ | HTT | P42858 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | SPR | P35270 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2318742 | 0.80 | ALDH1A1 (0.53) | CNR1ALDH1A1RAB9A | |
| SCHEMBL4080438 | 0.77 | CNR1 (1.00) | CNR1ALDH1A1KMT2ALMNAMEN1 | |
| SCHEMBL20812431 | 0.76 | CRBN (0.57) | — | |
| SCHEMBL2360650 | 0.76 | HSD11B1 (0.56) | CNR1ALDH1A1LMNASMN1; SMN2HSD11B1 | |
| SCHEMBL2320009 | 0.76 | HSD11B1 (0.56) | CNR1ALDH1A1LMNASMN1; SMN2HSD11B1 | |
| SCHEMBL826906 | 0.75 | ROCK1 (0.49) | ALDH1A1KDM4E | |
| SCHEMBL2318097 | 0.74 | MEN1 (0.53) | CNR1KMT2AMEN1SMN1; SMN2NPSR1 | |
| SCHEMBL23626145 | 0.74 | HSD11B1 (0.57) | CNR1ALDH1A1LMNASMN1; SMN2NPSR1 | |
| SCHEMBL2854511 | 0.73 | SPR (0.64) | KMT2AMEN1SMN1; SMN2HSD11B1RAB9A | |
| SCHEMBL17324820 | 0.73 | ROCK1 (0.51) | ALDH1A1SMN1; SMN2RAB9ANPC1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1928840-B1 | 1H-Pyrazole-4-carboxamides, their preparation and their use as 11-beta-hydroxysteroid dehydrogenase inhibitors | HOFFMANN LA ROCHE (CH) | 2011-08-10 | — | — | EP | claimed |
| EP-1928840-A1 | 1H-PYRAZOLE 4-CARBOXYLAMIDES, THEIR PREPARATION AND THEIR USE AS 11BETA-HYDROXYSTEROID DEHYDROGENASE | F. Hoffmann-Roche AG (CH) | 2008-06-11 | — | — | EP | claimed |
| WO-2006106052-A1 | PYRAZOLES | F. HOFFMANN-LA ROCHE AG (CH) | 2006-10-12 | — | — | WO | claimed |
| EP-1928840-B1 | 1H-Pyrazole-4-carboxamides, their preparation and their use as 11-beta-hydroxysteroid dehydrogenase inhibitors | HOFFMANN LA ROCHE (CH) | 2011-08-10 | — | — | EP | disclosed |
| EP-1928840-B1 | 1H-Pyrazole-4-carboxamides, their preparation and their use as 11-beta-hydroxysteroid dehydrogenase inhibitors | HOFFMANN LA ROCHE (CH) | 2011-08-10 | — | — | EP | disclosed |
| EP-1928840-A1 | 1H-PYRAZOLE 4-CARBOXYLAMIDES, THEIR PREPARATION AND THEIR USE AS 11BETA-HYDROXYSTEROID DEHYDROGENASE | F. Hoffmann-Roche AG (CH) | 2008-06-11 | — | — | EP | disclosed |
| US-7345058-B2 | (1-Methyl-5-phenyl-1H-pyrazol-4-yl)-(trans-octahydro-isoquinolin-2-yl)methanone; 11 beta -hydroxysteroid dehydrogenase inhibitor; upregulation of phosphoenolpyruvate carboxykinase (PEPCK) and glucose-6-phosphatase (G6Pase); antidiabetic agent; type II diabetes mellitus and metabolic syndrome | HOFFMANN-LA ROCHE INC. (US) | 2008-03-18 | — | — | US | disclosed |
| US-7345058-B2 | (1-Methyl-5-phenyl-1H-pyrazol-4-yl)-(trans-octahydro-isoquinolin-2-yl)methanone; 11 beta -hydroxysteroid dehydrogenase inhibitor; upregulation of phosphoenolpyruvate carboxykinase (PEPCK) and glucose-6-phosphatase (G6Pase); antidiabetic agent; type II diabetes mellitus and metabolic syndrome | HOFFMANN-LA ROCHE INC. (US) | 2008-03-18 | — | — | US | disclosed |
| WO-2006106052-A1 | PYRAZOLES | F. HOFFMANN-LA ROCHE AG (CH) | 2006-10-12 | — | — | WO | disclosed |
| US-20060223852-A1 | Pyrazoles | GILLESPIE PAUL | 2006-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060223852-A1 | Pyrazoles | GPR119, PDK2, PC | CNR1 1910/4885ALDH1A1 333/4885KMT2A 4095/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.